Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Clinical, radiological, bacteriological and overall outcomes during the trial.

From: Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study

Evaluation Month IFN gamma Placebo P (test)
Overall response      
Responders (a) (intention-to- treat) 6 13/18 (72.2%) 5/14 (35.7%) 0.037 (χ2)
  18 12/18 (66.7%) 4/14 (28.6%) 0.030 (χ2)
Responders (last evaluation)    15/18 (83.3%) 5/14 (35.7%) 0.005 (χ2)
Clinical      
Dyspnea 0 15/18 (83.3%) 13/14 (92.9%)  
  6 1/15 (6.7%) 3/9 (33.3%) 0.27 (FE)
  18 1/13 (7.7%) 3/8 (37.5%) 0.25 (FE)
BMI (kg/m2), mean ± SD 0 21.1 ± 3.5 (N = 18) 18.7 ± 2.8 (N = 14)  
  6 21.8 ± 3.7 (N = 14) 19.4 ± 3.0 (N = 9) 0.88 (St)
  18 22.9 ± 4.4 (N = 13) 19.9 ± 3.9 (N = 8) 0.15 (St)
Good general status (intention-to-treat) 0 3/18 (16.7%) 4/14 (28.6%)  
  6 13/18 (72.2%) 5/14 (35.7%) 0.037 (χ2)
  18 12/18 (66.7%) 4/14 (28.6%) 0.03 (χ2)
Improvement (b) (intention-to-treat) 6 13/18 (72.2%) 5/14 (35.7%) 0.037 (χ2)
  18 12/18 (66.7%) 4/14 (28.6%) 0.03 (χ2)
Radiological      
Lesion extension 0 Adv 12 (66.7%) 11(78.6%)  
   Mod 5 (27.8%) 3 (21.4%)  
   Min 1 (5.6%) 0  
  6 Adv 2 (13.3%) 5 (55.6%) 1.00c (FE)
   Mod 12 (80.0%) 3 (33.3%)  
   Min 1 (6.7%) 1 (11.1%)  
  18 Adv 1 (7.7%) 2 (25.0%) 0.085c (FE)
   Mod 5 (38.5%) 5 (62.5%)  
   Min 7 (53.8%)d 1 (12.5%)  
Improvement (intention to treat) 6 12/18 (66.7%) 6/14 (42.8%) 0.32 (χ2)
  18 13/18 (72.2%) 4/14 (28.6%) 0.036 (χ2)
Cavitary lesions disappearance    5/12 (41.7%) 1/12 (8.3%) 0.15 (FE)
Bacteriological      
Sputum- Direct (+) 0 14/18 (77.8%) 10/14 (71.4%)  
  Cod. 7 ± 4 8 ± 8  
  6 1/15 (6.7%) 2/10 (20.0%) 0.54 (FE)
  Cod. 0 ± 0 0 ± 2 0.28 (MW)
  18 1/13 (7.7%) 3/8 (37.5%) 0.253 (FE)
  Cod. 0 ± 0 0 ± 7 0.112 (MW)
  Relapse 1/13 (7.7%) 3/8 (37.5%) 0.25 (FE)
Sputum- Culture (+) 0 18 (100%) 14 (100%)  
  Cod. 8 ± 2 9 ± 4  
  6 2/15 (13.3%) 2/10 (20.0%) 1.00 (FE)
  Cod. 0 ± 0 0 ± 2 0.60 (MW)
  18 1/13 (7.7%) 4/8 (50.0%) 0.11 (FE)
  Cod. 0 ± 0 0 ± 8 0.042 (MW)
  Relapse 1/13 (7.7%) 3/8 (37.5%) 0.25 (FE)
  1. (St): Student's t test; (MW): Mann-Whitney's U test; all binary variable comparisons were with the Fisher's exact test.
  2. (a) All overall responses were complete except for one IFN group case at month 6 with partial response.
  3. (b) General clinical status improvement if the patient passed from "bad" to "moderate" or from "moderate" to "good".
  4. Adv: Advanced; Mod: Moderate; Min: Minimum; (c) Combining advanced-moderate;
  5. dOne of them had lesions disappearance at this time.